Androgenetic Alopecia Treatment Guidelines

First-Line Medical Treatments

The American College of Dermatology recommends starting with topical minoxidil 5% twice daily or oral finasteride 1 mg daily for men with androgenetic alopecia, with finasteride demonstrating superior efficacy in head-to-head trials 1, 2
For women, the American Academy of Dermatology recommends topical minoxidil as the only FDA-recognized first-line treatment for female androgenetic alopecia 1

The International Society of Hair Restoration Surgery recommends adding PRP therapy when first-line treatments produce suboptimal results or to enhance outcomes, using nonactivated PRP combined with continued topical minoxidil for superior efficacy 1, 2, 3
Nonactivated PRP produces 31% greater improvements in hair density compared to activated preparations 3
Initial treatment phase consists of 3-5 sessions spaced exactly one month apart, with maintenance every 6 months 1, 2, 3
Combination therapy with PRP plus topical minoxidil 5% is significantly more effective than either treatment alone 1, 2, 3

The American Academy of Dermatology suggests that PRF shows promise as a potentially superior alternative to PRP with theoretical advantages including lower cost, easier preparation, and similar efficacy 2, 3

The British Association of Dermatologists states that oral zinc and isoprinosine have been proven ineffective in controlled trials for alopecia areata and should not be used 4
No high-quality evidence supports nutritional supplements specifically for androgenetic alopecia treatment 4

Start with topical minoxidil 5% twice daily (men) or 2% twice daily (women) as baseline therapy, and consider adding oral finasteride 1 mg daily for men with inadequate response after 4 months 1, 2
If response remains suboptimal after 6-12 months of combination therapy, add PRP injections while continuing minoxidil 1, 2, 3

Never discontinue minoxidil once started, as all gains will be lost 1
Never activate PRP, as activation reduces efficacy by 31% 3
Avoid using PRP as monotherapy, and always combine with topical minoxidil for optimal outcomes 1, 3

Trichoscopic measurement of hair density (hairs / cm²) and the terminal‑to‑vellus hair ratio is recommended as an objective tool for evaluating therapy effectiveness at three‑month intervals. 5

No head‑to‑head randomized controlled trials comparing platelet‑rich fibrin (PRF) with platelet‑rich plasma (PRP) have been published as of 2023, indicating a current lack of high‑quality comparative evidence. 6
PRF is theorized to offer potential advantages such as lower cost, easier preparation, and sustained release of growth factors, but these benefits remain unproven without direct trial data. 5

Individual genetic factors significantly affect response to all androgenetic alopecia treatments, accounting for the variable outcomes observed across patients. 5

Patients should receive oral finasteride 1 mg daily for at least three months before any visible improvement in hair growth can be expected; assessments made earlier may not reflect true efficacy. This recommendation is based on evidence from the British Journal of Dermatology (2003) 7, 8.